Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).

被引：1
|
作者：
Sher, Amna Falak [1 ]
Bruce, Justine Yang [2 ]
Gabrail, Nashat Y. [3 ]
Anderson, Ian Churchill [4 ]
Patrikidou, Anna [5 ]
Sanborn, Rachel E. [6 ]
Cho, Jae Yong [7 ]
Lee, Arielle Shebay [8 ]
Lee, Jong-Seok [9 ]
Nott, Louise M. [10 ]
Oh, Do-Youn [11 ]
Oh, Sang Cheul [12 ]
Oh, Sung Yong [13 ]
Wang Yinghui [14 ]
Wang Zejing [14 ]
Guthrie, Troy H. [15 ]
机构：
[1] Stony Brook Univ Hosp, Stony Brook, NY USA
[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[3] Gabrail Canc Ctr Res LLC, Canton, OH USA
[4] St Joseph Heritage Healthcare, Santa Rosa, CA USA
[5] Sarah Cannon Res Inst, London, England
[6] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA
[7] Yonsei Univ, Gangnam Severance Hosp, Seoul, South Korea
[8] UT Hlth, HOPE Canc Ctr East Texas, Tyler, TX USA
[9] Seoul Natl Univ, Bundang Hosp, Seongnam Si, South Korea
[10] Royal Hobart Hosp, Hobart, Tas, Australia
[11] Seoul Natl Univ Hosp, Seoul, South Korea
[12] Korea Univ, Guro Hosp, Seoul, South Korea
[13] Dong A Univ Hosp, Busan, South Korea
[14] Seattle Genet Inc, Bothell, WA USA
[15] 21st Century Oncol, Jacksonville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.TPS185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS185
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study
    Philippou, Yiannis
    Protheroe, Andrew S.
    Bryant, Richard J.
    EUROPEAN UROLOGY, 2020, 77 (06) : 759 - 760
  • [32] Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
    Chi, Kim N.
    Higano, Celestia S.
    Blumenstein, Brent
    Ferrero, Jean-Marc
    Reeves, James
    Feyerabend, Susan
    Gravis, Gwenaelle
    Merseburger, Axel S.
    Stenzl, Arnulf
    Bergman, Andries M.
    Mukherjee, Som D.
    Zalewski, Pawel
    Saad, Fred
    Jacobs, Cindy
    Gleave, Martin
    de Bono, Johann S.
    LANCET ONCOLOGY, 2017, 18 (04): : 473 - 485
  • [33] Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer
    Shore, Neal D.
    Schellhammer, Paul F.
    Tutrone, Ronald F.
    Mariados, Neil F.
    Harrelson, Stacey S.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (05) : 416 - 422
  • [34] Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer
    Hussain, A.
    DiPaola, R. S.
    Baron, A. D.
    Higano, C. S.
    Tchekmedyian, N. S.
    Johri, A. R.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 492 - 497
  • [35] A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
    Armstrong, Andrew J.
    Shen, Tong
    Halabi, Susan
    Kemeny, Gabor
    Bitting, Rhonda L.
    Kartcheske, Patricia
    Embree, Elizabeth
    Morris, Karla
    Winters, Carolyn
    Jaffe, Tracy
    Fleming, Mark
    George, Daniel J.
    CLINICAL GENITOURINARY CANCER, 2013, 11 (04) : 397 - 406
  • [36] A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
    Armstrong, Andrew J.
    Shen, Tong
    Halabi, Susan
    Kemeny, Gabor
    Bitting, Rhonda Lynn
    Kartcheske, Patricia
    Embree, Elizabeth
    Morris, Karla
    Winters, Carolyn
    Jaffe, Tracy
    Fleming, Mark T.
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [37] Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD) a multicentre, open-label, phase 2 trial
    Smith, Matthew R.
    Scher, Howard, I
    Sandhu, Shahneen
    Efstathiou, Eleni
    Lara, Primo N.
    Yu, Evan Y.
    George, Daniel J.
    Chi, Kim N.
    Saad, Fred
    Stahl, Olof
    Olmos, David
    Danila, Daniel C.
    Mason, Gary E.
    Espina, Byron M.
    Zhao, Xin
    Urtishak, Karen A.
    Francis, Peter
    Lopez-Gitlitz, Angela
    Fizazi, Karim
    LANCET ONCOLOGY, 2022, 23 (03): : 362 - 373
  • [38] A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
    Pook, David
    Geynisman, Daniel M.
    Carles, Joan
    de Braud, Filippo
    Joshua, Anthony M.
    Perez-Gracia, Jose Luis
    Perez, Casilda Llacer
    Shin, Sang Joon
    Fang, Bruno
    Barve, Minal
    Maruzzo, Marco
    Bracarda, Sergio
    Kim, Miso
    Kerloeguen, Yannick
    Gallo, Jorge Daniel
    Maund, Sophia L.
    Harris, Adam
    Huang, Kuan-Chieh
    Poon, Victor
    Sutaria, Dhruvitkumar S.
    Gurney, Howard
    CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3292 - 3300
  • [39] Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study
    Dreicer, R.
    Agus, D. B.
    MacVicar, G. R.
    Wang, J.
    MacLean, D.
    Stadler, W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
    Dillon, Patrick
    Basho, Reva
    Han, Hyo S.
    Kolberg, Hans-Christian
    Tkaczuk, Katherine
    Zahrah, George
    Gion, Maria
    Voss, Herman
    Meisel, Jane
    Pluard, Timothy
    Fox, Jenny
    Oliveira, Mafalda
    Brown-Glaberman, Ursa
    Stringer-Reasor, Erica
    Manso, Luis
    Kuemmel, Sherko
    Chen, Lin Chi
    Wu, Sheng
    Croft, Brandon
    Boni, Valentina
    CANCER RESEARCH, 2023, 83 (05)
12345